Clinical Trial Update: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) [Phase 2]

View source ↗

Summary

This is a Phase 2 master protocol evaluating SAR444245 in combination with other anticancer therapies for several gastrointestinal cancers; the study has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• SAR444245

Snippet

Sponsor: Sanofi | Conditions: Oesophageal Squamous Cell Carcinoma, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-07-01